| Document |
Document Title |
|
WO/2006/061193A1 |
The present invention relates to novel indenyl derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
|
|
WO/2006/059245A2 |
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, ...
|
|
WO/2006/058905A1 |
The present invention relates to compounds that interact with ion channels. In particular, the invention relates to compounds having the structural Formula having the structural Formula (I), (II), (III) or (IV), stereoisomers, tautomers,...
|
|
WO/2006/055184A2 |
The present invention is directed to novel heterocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
|
|
WO/2006/054102A1 |
The present invention pertains to synthetic analogues of microcin B17 component units, methods of making and using these analogues, including, for example, as inhibitors of DNA gyrase. More particularly, the present invention pertains to...
|
|
WO/2006/055837A2 |
A process for preparing (4S,5R)-5-carboxymethyl-2,2-dimethyl-4-phenyl-oxazolidine-3-
carboxylic acid t-butyl ester, an intermediate in the preparation of anticancer compounds having a taxane skeleton, such as paclitaxel, docetaxol, etc.
|
|
WO/2006/051408A1 |
Provided herein are novel substituted phenyloxazolidinones and to processes for the synthesis thereof. Also provided are pharmaceutical compositions comprising one or more compounds described herein. The compounds described can be useful...
|
|
WO/2006/051704A1 |
An imine compound represented by the formula (X) (wherein A represents a heterocyclic group; R1, R2, and R3 each represents hydrogen, halogeno, C1-10 alkyl optionally substituted by haloaryl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-10 alkox...
|
|
WO/2006/046595A1 |
Disclosed are an optically active 4,4-disubstituted oxazolidine derivative and a method for producing the same. Specifically disclosed is an optically active 4,4-disubstituted oxazolidine derivative represented by the following formula (...
|
|
WO/2006/047504A1 |
The invention relates to compounds of Formula (I), wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, ...
|
|
WO/2006/045350A1 |
The invention relates to novel heterocyclic compounds of formula (I) wherein R1, D, W, T and T' have the meaning cited in the claim 1. Said compounds are SGK-inhibitors and can be used in the treatment of SGK-related diseases and disorde...
|
|
WO/2006/044415A2 |
Peri-substituted, fused bicyclic ring carboxylic acids useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed.
|
|
WO/2006/045088A2 |
The dispersion of fillers such as carbon black, oxidized carbon black, silica, other mineral fillers, or mixtures thereof in polymeric compositions is improved by the use of a polymer-filler coupling compound, Q-A-B. In polymer-filler co...
|
|
WO/2006/044000A1 |
Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula (I). A representative exam...
|
|
WO/2006/044961A1 |
The present invention relates to modulators of PPAR-gamma of formula (I), and to processes for the preparation and use of the same. Such PPAR-gamma modulators are useful in the treatment of metabolic diseases and disorders.
|
|
WO/2006/044456A1 |
The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particu...
|
|
WO2005030705A9 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO/2006/037480A1 |
The invention is concerned with hexafluoroisopropanol substituted ether derivatives of formula (I), wherein Rl to R3 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. The...
|
|
WO/2006/038606A1 |
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...
|
|
WO/2006/037775A1 |
Enantiopure heterocyclic compound Enantiopure heterocyclic compound of formula (I) in which J is chosen from C, N, O and S; Z is H or a group for protecting the amino functional group, R3 denotes H or an organic residue, m is 0, 1 or 2 a...
|
|
WO/2006/038100A1 |
The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as an...
|
|
WO/2006/034605A1 |
The present invention relates to azabicyclic ring ammoniums of general formula I in which the definition of each radical is described in the specification and/or their pharmaceutically acceptable salts and hydrates; pharmaceutical compos...
|
|
WO/2006/034296A2 |
The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer’s disease.
|
|
WO/2006/034277A1 |
The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer’s disease.
|
|
WO/2006/032165A1 |
The present invention relates to 5-Membered-N-heterocyclic compounds of formula (I), and/or the salts and the hydrates thereof; and to the pharmaceutical compositions comprising such compounds, and the use of such compounds in treatment ...
|
|
WO/2006/030753A1 |
A new medicinal use of E-4-[4-(5-methyl-2phenyl-4-oxazolylmethoxy)benzyloxyimino]
-4-phenylbutyric acid, Z-2-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino
]-2-(4-phenoxyphenyl)acetic acid, 2-[2-propyl-3[3-[2-ethyl-4-(4-flu...
|
|
WO/2006/030211A2 |
Compounds of formula: (I) are found to antagonise N-type calcium channels wherein: - A is a 5- to 10-membered heteroaryl or heterocyclyl moiety, said moiety being optionally fused to a phenyl, 5- to 6-membered heteroaryl, C3-C6 carbocycl...
|
|
WO/2006/028963A2 |
The present invention relates to substituted heterocyclic compounds and compositions comprising a substituted heterocyclic compound. The present invention also relates to methods for preventing or treating various diseases and disorders ...
|
|
WO/2006/028972A2 |
Mercaptoamide compounds, represented by Formulas (IA), (IB), (IIA), and (IIB): or a pharmaceutically acceptable salt thereof, inhibit histone deacetylase enzyme and are useful for the treatment and/or prevention of various infections, ca...
|
|
WO/2006/027788A1 |
The invention relates to a process for the preparation of N-carboxyanhydrides by reaction of the corresponding amino acid with phosgene, diphosgene and/or triphosgene in a solvent medium, characterized in that the reaction is a least par...
|
|
WO2005063239A9 |
The invention relates to amid compounds of general formula (I), wherein groups and residuals A, B, b, W, X, Y, Z, R
|
|
WO/2006/026316A2 |
This invention provides estrogen receptor modulators of formula I, having the structure (I) wherein Q1 Q2, R1, R2 R2a, R3,R3a, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.
|
|
WO/2006/022794A1 |
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of tricyclic compounds that are useful as such age...
|
|
WO/2006/018116A1 |
The invention relates to aryl-cycloalkyl substituted alkanoic acid derivatives in addition to the physiologically compatible salts thereof and physiologically functional derivatives. The invention also relates to compounds of formula (I)...
|
|
WO/2006/019833A1 |
The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and us...
|
|
WO/2006/018118A1 |
The invention relates to compounds of formula (I), wherein R represents H, CF3; R1 represents H, CF3, a (C1-C6)-alkyl, a phenyl, a phenoxy; R2 represents H, a (C1-C4)-alkyl, O-(C1-C4)-alkyl, CF3; or R1 and R2 represent, together with the...
|
|
WO/2006/018115A1 |
The invention relates to compounds of formula (I), wherein R1 represents H, (C1-C6)-alkyl; R2 represents H, an O-(C1-C3)-alkyl, CF3; or R1 and R2 represent, together with the phenyl-ring, a condensed naphthyl; R3 represents a (C1-C6)-alk...
|
|
WO/2006/016399A1 |
A compound which inhibits the production of IL-6 and/or TNF&agr by inflammatory cytokines and is useful in the prevention of or treatments for diseases such as various inflammatory diseases in which these cytokines participate and autoim...
|
|
WO/2006/014015A1 |
Unsaturated aminodiols useful as the raw material in the synthesis of sphingomyelin effective for drug delivery systems or the like can be produced through easy and general means by reacting an unsaturated aminodiol represented by the ge...
|
|
WO2005112913B1 |
Dibenz?furan-4,6-dicarboxylic acid core structures having an aromatic substituent appended onto the at the C1 position using three different types of linkages are disclosed herein and shown to afford exceptional amyloidogenesis inhibitor...
|
|
WO/2006/014413A1 |
Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atheros...
|
|
WO/2006/014134A1 |
Compounds of formula: (chemical formula to be inserted here - please see paper copy) wherein Ar1 is as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepar...
|
|
WO/2006/014357A1 |
Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atheros...
|
|
WO/2006/010968A1 |
The new aryloxy acetic acid amide derivatives of formula (I) where R1 and R2 are the same or different and can be hydrogen atom or C1-4 alkanoylamido group optionally substituted by halogen atom or C1-4 alkyl-sulfonylamido group or N'-( ...
|
|
WO/2006/011466A1 |
Disclosed are a compound and pharmaceutically acceptable salts thereof represented by the general formula (1) below. (In the formula (1), R1, R2, R3, R4 and X are the same as R1, R2, R3, R4 and X defined in the description.)
|
|
WO/2006/008754A1 |
The present invention provides a novel process for preparation of 5aminomethyl substituted oxazolidinones, key intermediates for oxazolidinone antibacterials including linezolid. Thus, the key intermediate of linezolid is prepared by a...
|
|
WO/2006/009134A1 |
A novel fungicide that exhibits a wide disease control spectrum against pathogenic fungi acting on various crops and helps resolve worsening resistant strain problems. There are provided diamine derivatives of the formula (1), a process ...
|
|
WO/2006/006832A1 |
The present invention relates to a novel sulfamide derivative, a pharmaceutically acceptable salt thereof and a pharmaceutical composition for upregulation of lipid metabolism comprising same as an active ingredient.
|
|
WO/2006/004215A1 |
Benzoxazoles represented by the general formula (1) and being useful as herbicides: wherein R1 to R4 are each H, halogeno, NO2, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 haloalkoxy, C2-5 alkanoyl, formyl, C2-6 alkoxycarbonyl, or carboxyl; R5 ...
|
|
WO/2006/003495A1 |
The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists...
|
